Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation

Tomohiko Tanigawa; Masatoshi Sakurai; Jun Kato; Kota Mizuno; Shinya Fujita; Yuya Koda; Taku Kikuchi; Takayuki Shimizu; Shinichiro Okamoto; Keisuke Kataoka

doi:10.1007/s00277-021-04586-w

Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation

Tomohiko Tanigawa, Masatoshi Sakurai, Jun Kato, Kota Mizuno, Shinya Fujita, Yuya Koda, Taku Kikuchi, Takayuki Shimizu, Shinichiro Okamoto, Keisuke Kataoka

内科学(血液)

研究成果: Letter › 査読

1 被引用数 (Scopus)

本文言語	English
ページ（範囲）	723-724
ページ数	2
ジャーナル	Annals of Hematology
巻	101
号	3
DOI	https://doi.org/10.1007/s00277-021-04586-w
出版ステータス	Published - 2022 3月

ASJC Scopus subject areas

血液学

文献へのアクセス

10.1007/s00277-021-04586-w

他のファイルとリンク

引用スタイル

Tanigawa, T, Sakurai, M , Kato, J, Mizuno, K, Fujita, S, Koda, Y, Kikuchi, T, Shimizu, T, Okamoto, S & Kataoka, K 2022, 'Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation', Annals of Hematology, vol. 101, no. 3, pp. 723-724. https://doi.org/10.1007/s00277-021-04586-w

@article{289cf44ad84649d1ab40a42323b6c243,

title = "Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation",

author = "Tomohiko Tanigawa and Masatoshi Sakurai and Jun Kato and Kota Mizuno and Shinya Fujita and Yuya Koda and Taku Kikuchi and Takayuki Shimizu and Shinichiro Okamoto and Keisuke Kataoka",

note = "Funding Information: MS received research funding from MSD K.K. and Nippon Shinyaku Co., Ltd., personal fees from Nippon Shinyaku Co., Ltd., Takeda Pharmaceutical, Eisai Co., Ltd., Chugai Pharmaceutical, Alexion Pharmaceuticals Inc., and Otsuka Pharmaceutical, outside of the submitted work; TK received personal fees from Takeda Pharmaceutical, outside of the submitted work; KK received research funding from Otsuka Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Chordia Therapeutics, Eisai Co., Ltd., Mochida Pharmaceutical, JCR Pharmaceuticals, Otsuka Pharmaceutical, Ono Pharmaceutical, and Kyowa Kirin, and is a co-founder and shareholder in Asahi Genomics, outside of the submitted work. All other authors declare no competing interests. ",

year = "2022",

month = mar,

doi = "10.1007/s00277-021-04586-w",

language = "English",

volume = "101",

pages = "723--724",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation

AU - Tanigawa, Tomohiko

AU - Sakurai, Masatoshi

AU - Kato, Jun

AU - Mizuno, Kota

AU - Fujita, Shinya

AU - Koda, Yuya

AU - Kikuchi, Taku

AU - Shimizu, Takayuki

AU - Okamoto, Shinichiro

AU - Kataoka, Keisuke

N1 - Funding Information: MS received research funding from MSD K.K. and Nippon Shinyaku Co., Ltd., personal fees from Nippon Shinyaku Co., Ltd., Takeda Pharmaceutical, Eisai Co., Ltd., Chugai Pharmaceutical, Alexion Pharmaceuticals Inc., and Otsuka Pharmaceutical, outside of the submitted work; TK received personal fees from Takeda Pharmaceutical, outside of the submitted work; KK received research funding from Otsuka Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Chordia Therapeutics, Eisai Co., Ltd., Mochida Pharmaceutical, JCR Pharmaceuticals, Otsuka Pharmaceutical, Ono Pharmaceutical, and Kyowa Kirin, and is a co-founder and shareholder in Asahi Genomics, outside of the submitted work. All other authors declare no competing interests.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85109394161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109394161&partnerID=8YFLogxK

U2 - 10.1007/s00277-021-04586-w

DO - 10.1007/s00277-021-04586-w

M3 - Letter

C2 - 34235557

AN - SCOPUS:85109394161

SN - 0939-5555

VL - 101

SP - 723

EP - 724

JO - Annals of Hematology

JF - Annals of Hematology

IS - 3

ER -